These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
377 related articles for article (PubMed ID: 31314847)
1. Neurofilament light chain in the assessment of patients with multiple sclerosis. Domingues RB; Fernandes GBP; Leite FBVM; Senne C Arq Neuropsiquiatr; 2019 Jul; 77(6):436-441. PubMed ID: 31314847 [TBL] [Abstract][Full Text] [Related]
2. A comparative study of CSF neurofilament light and heavy chain protein in MS. Kuhle J; Plattner K; Bestwick JP; Lindberg RL; Ramagopalan SV; Norgren N; Nissim A; Malaspina A; Leppert D; Giovannoni G; Kappos L Mult Scler; 2013 Oct; 19(12):1597-603. PubMed ID: 23529999 [TBL] [Abstract][Full Text] [Related]
3. The role of blood and CSF biomarkers in the evaluation of new treatments against multiple sclerosis. Lycke J; Zetterberg H Expert Rev Clin Immunol; 2017 Dec; 13(12):1143-1153. PubMed ID: 29090607 [TBL] [Abstract][Full Text] [Related]
4. Value contribution of blood-based neurofilament light chain as a biomarker in multiple sclerosis using multi-criteria decision analysis. Monreal E; Ruiz PD; San Román IL; Rodríguez-Antigüedad A; Moya-Molina MÁ; Álvarez A; García-Arcelay E; Maurino J; Shepherd J; Cabrera ÁP; Villar LM Front Public Health; 2024; 12():1397845. PubMed ID: 38711771 [TBL] [Abstract][Full Text] [Related]
7. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort. Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051 [TBL] [Abstract][Full Text] [Related]
8. Can CSF biomarkers predict future MS disease activity and severity? Magliozzi R; Cross AH Mult Scler; 2020 Apr; 26(5):582-590. PubMed ID: 31965889 [TBL] [Abstract][Full Text] [Related]
9. High neurofilament levels are associated with clinically definite multiple sclerosis in children and adults with clinically isolated syndrome. van der Vuurst de Vries RM; Wong YYM; Mescheriakova JY; van Pelt ED; Runia TF; Jafari N; Siepman TA; Melief MJ; Wierenga-Wolf AF; van Luijn MM; Samijn JP; Neuteboom RF; Hintzen RQ Mult Scler; 2019 Jun; 25(7):958-967. PubMed ID: 29774770 [TBL] [Abstract][Full Text] [Related]
10. Increased cerebrospinal fluid neurofilament light chain in central nervous system inflammatory demyelinating disease. Peng L; Bi C; Xia D; Mao L; Qian H Mult Scler Relat Disord; 2019 May; 30():123-128. PubMed ID: 30771578 [TBL] [Abstract][Full Text] [Related]
11. Serum and cerebrospinal fluid light neurofilaments and antibodies against them in clinically isolated syndrome and multiple sclerosis. Fialová L; Bartos A; Svarcová J; Zimova D; Kotoucova J; Malbohan I J Neuroimmunol; 2013 Sep; 262(1-2):113-20. PubMed ID: 23870535 [TBL] [Abstract][Full Text] [Related]
12. Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis. Kuhle J; Malmeström C; Axelsson M; Plattner K; Yaldizli O; Derfuss T; Giovannoni G; Kappos L; Lycke J Acta Neurol Scand; 2013 Dec; 128(6):e33-6. PubMed ID: 23763388 [TBL] [Abstract][Full Text] [Related]
13. Vitamin D and axonal injury in multiple sclerosis. Sandberg L; Biström M; Salzer J; Vågberg M; Svenningsson A; Sundström P Mult Scler; 2016 Jul; 22(8):1027-31. PubMed ID: 26462862 [TBL] [Abstract][Full Text] [Related]
14. Monitoring disease activity in multiple sclerosis using serum neurofilament light protein. Novakova L; Zetterberg H; Sundström P; Axelsson M; Khademi M; Gunnarsson M; Malmeström C; Svenningsson A; Olsson T; Piehl F; Blennow K; Lycke J Neurology; 2017 Nov; 89(22):2230-2237. PubMed ID: 29079686 [TBL] [Abstract][Full Text] [Related]
15. Heightened intrathecal release of axonal cytoskeletal proteins in multiple sclerosis is associated with progressive disease and clinical disability. Semra YK; Seidi OA; Sharief MK J Neuroimmunol; 2002 Jan; 122(1-2):132-9. PubMed ID: 11777552 [TBL] [Abstract][Full Text] [Related]